CXCL14/BRAK 蛋白, Human (Biotinylated)

CXCL14 (also known as breast and kidney-expressed chemokine (BRAK)), as a non-ELR CXC chemokine. CXCL14 displays chemotactic activity for monocytes but not for B and T cells. CXCL14 is involved in cancer, immune responses, and epithelial cell proliferation and migration. CXCL14 is a potent inhibitor of angiogenesis, and also shows antimicrobial activity^[1][2]. CXCL14/BRAK Protein, Human (Biotinylated), a Biotinylated CXCL14 protein, is produced in E. coli, and consists of 77 amino acids (S35-E111).

趋化因子 CXCL14 是一种高度保守的稳态趋化因子，在多种正常组织中组成型表达，包括脂肪、脑、乳腺、子宫颈、肺、肾和皮肤。CXCL14 参与感染性和炎症性疾病、血管生成和癌症^[1][2]。
在趋化因子中，CXCL14 在哺乳动物中高度保守，只有两种趋化因子小鼠和人类之间的氨基酸差异。CXCL14 有四个保守的半胱氨酸残基，形成二硫键7。而且，共同点是，N 末端的前 22 个氨基酸具有强疏水性，并充当信号肽，在分泌前被切割。与其他趋化因子一样，CXCL14 是一种趋化剂，尤其是对单核细胞而言，可诱导树突状细胞 (DC) 的成熟和迁移。然而，在没有前列腺素E2（PGE2）的情况下，单核细胞的CXCL14相关迁移较弱，表明PGE2是CXCL14相关趋化性所必需的。单核细胞对CXCL14和PGE2的反应是特异性的，B和T细胞没有任何趋化反应。除单核细胞外，CXCL14 还特异性增强 CD56+ 自然杀伤 (NK) 细胞的趋化性。CXCL14 负责免疫细胞的招募和成熟，并影响上皮细胞运动，有助于在正常上皮层内建立免疫监视。总体而言，CXCL14 负责免疫细胞的浸润、树突状细胞的成熟、主要组织相容性复合体 (MHC)-I 表达的上调以及细胞动员。虽然成纤维细胞来源的 CXCL14 具有肿瘤支持作用，但上皮细胞来源的 CXCL14 主要抑制肿瘤进展^[1][2]。
之前有很多关于 CXCL14 的研究已经显示出 CXCL14 的矛盾功能：肿瘤抑制与促进、细胞迁移增加与减少、血管生成与血管抑制、以及 CXCR4 抑制与激活与无作用。CXCL14通过直接结合IL-8和FGF2来抑制内皮细胞的趋化性，从而阻碍它们与人血管内皮细胞上的高亲和力受体的相互作用。此外，CXCL14 广泛调节各种类型免疫细胞的趋化性、分化和激活。此外，CXCL14 还具有抗菌活性，可有效清除呼吸道中肺炎链球菌的感染^[2]。

Recombinant human CXCL14 (5-2 ng/mL) induced dendritic cell attraction in head and neck squamous cell carcinoma (HNSCC). CXCL14 resultes in up-regulation of the expression of dendritic cell maturation markers, as well as enhanced proliferation of allogeneic T cells in MLR. Activation of dendritic cell with recombinant human CXCL14 is accompanied by up-regulation of NF-κB activity^[3].

Human

E. coli

Tag Free

O95715 (S35-E111)

9547  [NCBI]

Approximately 9.4 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O.

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Arezoo Gowhari Shabgah, et al. Chemokine CXCL14; a double-edged sword in cancer development. Int Immunopharmacol. 2021 Aug;97:107681.  [Content Brief]

  [2]. Joseph A Westrich, et al. The multifarious roles of the chemokine CXCL14 in cancer progression and immune responses. Mol Carcinog. 2020 Jul;59(7):794-806.  [Content Brief]

  [3]. Galina V Shurin, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005 May 1;174(9):5490-8.  [Content Brief]